STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
NCT00006475 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2013-02-21
Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective treatment for leukemia.
PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have chronic myelogenous leukemia in blast crisis.
Conditions
Interventions
- DRUG
-
imatinib mesylate
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ilana Monteleone · Novartis Pharmaceuticals
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-09-30
- Primary Completion
- 2002-12-31
- Completion
- 2002-12-31
Countries
- United States
Study Locations
More Related Trials
-
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
NCT00171223 ·Status: COMPLETED ·Phase: PHASE2
-
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
NCT00006343 ·Status: COMPLETED ·Phase: PHASE3
-
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase
NCT00514969 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
NCT00028847 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia
NCT00015860 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042003 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00039377 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042016 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00041990 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
NCT05947344 ·Status: RECRUITING ·Phase: PHASE1
-
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia
NCT00511303 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation
NCT00219726 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00022490 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years
NCT00219752 ·Status: COMPLETED ·Phase: PHASE2
-
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00012259 ·Status: COMPLETED ·Phase: PHASE2
-
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
NCT05030675 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
NCT00362466 ·Status: TERMINATED ·Phase: PHASE3
-
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
NCT00038649 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
NCT00777036 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
NCT00449761 ·Status: TERMINATED ·Phase: PHASE2
-
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
NCT01261312 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT01757639 ·Status: COMPLETED ·Phase: PHASE1
-
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
NCT00383474 ·Status: COMPLETED ·Phase: PHASE1
-
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00084916 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
NCT00333840 ·Status: COMPLETED ·Phase: PHASE3